Radiotherapy Market

Market Overview The global radiotherapy market is projected to expand from USD 6.81 billion in 2025 to USD 11.25 billion by 2031, growing at an 8.73% CAGR. Radiotherapy, a clinical method, uses ionizing radiation to damage the DNA of cancerous tissues, inhibiting cellular replication for either curative or palliative outcomes. The primary drivers for this growth include a rising global incidence of oncological disorders and a demographic shift towards an aging population, which is more prone to malignancies. Additionally, expanding healthcare reimbursement coverage in developing regions offers a fundamental structural impetus for market broadening, distinct from transient technological shifts. Despite these positive conditions, the high acquisition and operational costs of radiation delivery systems significantly impede widespread adoption, especially in markets with limited financial resources. This economic constraint exacerbates the disparity between infrastructure supply and escalating patient demand; for instance, the American Cancer Society projects 2,041,910 new cancer cases in the United States in 2025, emphasizing the critical need for economically viable solutions to address the increasing disease burden. Market Driver The integration of Artificial Intelligence (AI) and Machine Learning (ML) into treatment planning and delivery systems is fundamentally reshaping the market by enhancing therapeutic precision and addressing critical workflow inefficiencies. These technologies automate complex tasks like contouring and dose calculation, substantially reducing the time from diagnosis to treatment initiation while minimizing human error. Such operational acceleration is crucial for clinics managing high patient volumes, allowing for adaptive therapies that adjust to real-time anatomical changes. GE HealthCare reported in September 2025 that early adopters of their AI-supported Intelligent Radiation Therapy (iRT) solution reduced the time from simulation to treatment planning from seven days to just seven minutes. These dramatic efficiency gains are driving the replacement of legacy systems with AI-enabled platforms, thus fostering market growth through high-value equipment upgrades. Concurrently, supportive government initiatives and funding for healthcare infrastructure in both emerging and established markets serve as a robust catalyst for expanding radiotherapy accessibility. Public sector investment increasingly targets the modernization of oncology departments and bridging equipment gaps in underserved regions, directly stimulating procurement activities for linear accelerators and associated software. For example, the UK Government confirmed a £70 million investment in May 2025 to roll out new radiotherapy machines across 28 hospitals, aiming to cut waiting lists and improve cancer care. This capital injection highlights the vital role of state-level support in sustaining market momentum. Furthermore, the existing infrastructure continues to grow to meet global demand; Elekta, in July 2025, maintained an installed base of over 7,500 devices and software solutions worldwide, reflecting the expanding footprint of radiation medicine. Market Challenge The substantial acquisition and operational costs associated with advanced radiation delivery systems represent a significant barrier impeding the growth of the global radiotherapy market. Sophisticated platforms, particularly linear accelerators and proton therapy units, require immense capital expenditure that goes beyond the initial purchase, including specialized infrastructure, continuous maintenance, and highly skilled personnel. In markets with limited financial resources, this high barrier to entry prevents healthcare providers from scaling their capabilities to match patient volume. Consequently, many facilities cannot upgrade aging equipment or expand their footprint, directly stifling the adoption of newer technologies essential for market expansion. This financial strain is further intensified by contracting reimbursement models, which destabilize the return on investment necessary to justify such high-value procurements. When operational revenue declines, the economic viability of maintaining a state-of-the-art radiotherapy department is compromised, causing providers to halt capital investments. The American Society for Radiation Oncology noted a finalized Medicare Physician Fee Schedule reimbursement reduction of approximately 2.8 percent for radiation oncology services in 2025. Such fiscal contractions create an unfavorable economic environment that hinders infrastructure development, thereby restricting the market’s ability to bridge the widening gap between supply and the escalating global demand for cancer care. Market Trends The accelerated adoption of MRI-Guided Linear Accelerators is transforming the market by enabling real-time visualization of soft tissue during radiation delivery, a capability absent in conventional X-ray guided systems. This technology allows clinicians to reduce margins and safely escalate doses to tumors located near critical organs, driving procurement in high-end academic centers and specialized oncology networks. The clinical validity of this modality is increasingly supported by robust trial data, which justifies the high capital investment required for these platforms. Elekta reported in May 2025 that preliminary results from the ERECT trial demonstrated that MR-guided radiotherapy significantly preserved patient quality of life, reducing the incidence of erectile dysfunction at six months to 6% compared to 21% with conventional methods. Parallel to this, the expansion of Proton and Carbon Ion Therapy infrastructure signifies a shift toward particle-based modalities, which offer superior depth-dose characteristics for treating deep-seated malignancies. Despite the substantial initial capital requirements, the market is witnessing sustained investment in these facilities, driven by their ability to spare healthy tissue in pediatric and complex adult cases. This segment is growing as manufacturers successfully convert heavy equipment order backlogs into operational centers, validating the economic feasibility of these massive projects. IBA, for instance, reported in March 2025 a 7% year-over-year increase in total net sales to €498.2 million, a growth trajectory largely sustained by the strong execution and conversion of its proton therapy and accelerator backlog. Key Market Players * Canon Medical Systems Corporation * GE Healthcare Technologies Inc. * Elekta AB * ViewRay Technologies, Inc. * Mevion Medical Systems Inc. * BEBIG Medical GmbH * Siemens Healthineers AG * Accuray Incorporated * Isoray Inc. * Hitachi, Ltd. * ALCEN Group Report Scope In this report, the Global Radiotherapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: # Radiotherapy Market, By Type * External Beam Radiation Therapy * Internal Radiation Therapy * Systemic Radiation Therapy # Radiotherapy Market, By Application * kin & Lip Cancer * Breast Cancer * Prostate Cancer * Cervical Cancer * Lung Cancer * Others # Radiotherapy Market, By End-User * Hospitals * Research Institutes * Ambulatory * Radiotherapy Centers # Radiotherapy Market, By Region * North America United States Canada Mexico * Europe France United Kingdom Italy Germany Spain * Asia Pacific China India Japan Australia South Korea * South America Brazil Argentina Colombia * Middle East & Africa South Africa Saudi Arabia UAE Competitive Landscape Company Profiles: Detailed analysis of the major companies present in the Global Radiotherapy Market. Available Customizations: Global Radiotherapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: Company Information * Detailed analysis and profiling of additional market players (up to five).